JANX (STOCKS)
Janux Therapeutics, Inc. Common Stock
$13.130000
+0.020000 (+0.15%)
Prev close: $13.110000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- David Campbell
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $790.34M
- Employees
- 103
- P/E (TTM)
- -7.84
- P/B (TTM)
- 0.81
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
14
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $10.00M |
| Benefits Costs and Expenses | $111.90M |
| Costs And Expenses | $111.90M |
| Nonoperating Income/Loss | $42.39M |
| Operating Expenses | $154.29M |
| Research and Development | $115.15M |
| Other Operating Expenses | $39.13M |
| Operating Income/Loss | -$144.29M |
| Income/Loss From Continuing Operations After Tax | -$101.90M |
| Income/Loss From Continuing Operations Before Tax | -$101.90M |
| Net Income/Loss | -$101.90M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$101.90M |
| Net Income/Loss Available To Common Stockholders, Basic | -$101.90M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.67 |
| Diluted Earnings Per Share | -$1.67 |
| Basic Average Shares | 124,905,517 |
| Diluted Average Shares | 62,941,249 |
| Assets | $1.02B |
| Current Assets | $998.09M |
| Noncurrent Assets | $26.68M |
| Fixed Assets | $4.31M |
| Other Non-current Assets | $22.37M |
| Liabilities | $48.21M |
| Current Liabilities | $27.83M |
| Accounts Payable | $3.40M |
| Wages | $4.03M |
| Other Current Liabilities | $20.41M |
| Noncurrent Liabilities | $20.38M |
| Equity | $976.56M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $976.56M |
| Liabilities And Equity | $1.02B |
| Net Cash Flow From Operating Activities | -$70.42M |
| Net Cash Flow From Operating Activities, Continuing | -$70.42M |
| Net Cash Flow From Investing Activities | -$296.60M |
| Net Cash Flow From Investing Activities, Continuing | -$296.60M |
| Net Cash Flow From Financing Activities | $388.65M |
| Net Cash Flow From Financing Activities, Continuing | $388.65M |
| Net Cash Flow | $21.64M |
| Net Cash Flow, Continuing | $21.64M |
| Comprehensive Income/Loss | -$105.16M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$105.16M |
| Other Comprehensive Income/Loss | -$3.27M |